Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria
Celldex Therapeutics, Inc. (CLDX)
Last celldex therapeutics, inc. earnings: 11/12 08:01 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.celldex.com
Company Research
Source: GlobeNewswire
First to demonstrate clinical benefit in patients with chronic inducible urticaria (CIndU) in large, randomized, placebo-controlled study Favorable safety and tolerability Plan to advance CIndU into Phase 3 developmentCompany to host webcast call Monday at 8:00 am ET HAMPTON, N.J., Oct. 26, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today positive results from the Company’s Phase 2 clinical trial of barzolvolimab in two of the most common forms of chronic inducible urticaria (CIndU)—cold urticaria (ColdU) and symptomatic dermographism (SD). The study includes patients who remain symptomatic despite treatment with antihistamines. Barzolvolimab is a humanized monoclonal antibody that specifically binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity, which is required for mast cell function and survival. CIndU is characterized by the occurrence of hives or wheals that have an attributable trigger associated w
Show less
Read more
Impact Snapshot
Event Time:
CLDX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CLDX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CLDX alerts
High impacting Celldex Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CLDX
News
- Celldex Therapeutics, Inc. (NASDAQ: CLDX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.MarketBeat
- Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory DiseasesGlobeNewswire
- Celldex Therapeutics to Present at Upcoming Investor ConferencesGlobeNewswire
- Celldex Therapeutics Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]Yahoo! Finance
- Celldex Therapeutics, Inc. (NASDAQ: CLDX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.MarketBeat
CLDX
Earnings
- 11/6/24 - Beat
CLDX
Sec Filings
- 11/20/24 - Form 4
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- CLDX's page on the SEC website